TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01635985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: solution for injection, administered as intravenous infusion Corr to total dose of 250 µg AZD5423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: dry powder inhaled via Turbuhaler, corr to approximately 200 µg lung deposited dose AZD5423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: dry powder inhaled via New Dry Powder Inhaler, corr to approximately 200 µg lung deposited dose AZD5423
Study: NCT04421222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Once daily dose of apalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Once daily dose of apalutamide
Study: NCT04421222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Once daily dose of apalutamide
Study: NCT03150511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesamorelin 2 Milligrams (MG)
Description: Daily self-administered study drug
Study: NCT03155620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study: NCT00695279

Intervention type: PROCEDURE
Intervention: Venipuncture
Description: Blood draw
Study: NCT03155620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT03831464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: The intervention will consist in IMP treatment during 30 months with half of the patients treated with Metformin Glucophage SR. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.~During the first month of the trial a dose of 1x500mg will be used in order to avoid as much as possible some well-known mainly gastrointestinal side effects of metformin treatment .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The intervention will consist in IMP treatment during 30 months with half of the patients treated with matched placebo. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.
Study: NCT04713254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: 10, 20, 30 mg/day oral capsules on Day 5-18

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 4 mg syrup, oral single dose on Day 1 and Day 15

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: 100 mg tablets, oral single dose on Day 1 and Day 15

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: 100 mg tablets, oral single dose on Day 3 and Day 17
Study: NCT02810717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: theta-burst stimulation using a MagPro X1000
Description: TBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS over left DLPFC: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. Trains will be repeated 20 to reach a total number of 600 pulses per session. cTBS over right DLPFC: cTBS will comprise uninterrupted bursts to reach a total number of 600 pulses per session. Two sessions per day, separated by 60 minutes; 30 Sessions in total over 3 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation using a MagPro X1000
Description: Sham TBS with the coil set at 45° against the skull will be performed over left and right dorsolateral prefrontal cortex for a period of three weeks
Study: NCT02145260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate)
Description: A lower dialysate sodium will bes used in the active comparator arm (138 mmol/L)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)
Description: A higher dialysate sodium will be used in the experimental arm (142 mmol/L)
Study: NCT01529788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Right lateral orbital injection of Botox Cosmetic or Dysport
Description: Right lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL \[7.5 units\] per injection point) divided among 4 injection points (0.05mL \[2.5units\]) on Day 0 of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Left lateral orbital injection of Botox Cosmetic or Dysport
Description: Left lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL \[7.5 units\] per injection point) divided among 4 injection points (0.05mL \[2.5units\]) on Day 0 of the study
Study: NCT02880280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Menopausal Gonadotropin
Description: Human Menopausal Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
Study: NCT03155620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT02880280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin
Description: Human Chorionic Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin
Description: Human Chorionic Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
Study: NCT03832517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single intravenous doses of RC-01
Description: Intravenous single escalating doses of RC-01

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single intravenous doses of placebo
Description: Intravenous single doses of placebo to match RC-01

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple intravenous doses of RC-01
Description: Multiple ascending doses of RC-01 given intravenously two or three times daily for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple intravenous doses of placebo
Description: Multiple doses of placebo to match RC-01 given intravenously two or three times daily for 10 days
Study: NCT04905472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular prosthesis/implant
Description: The intervention is a vestibular prosthesis which our collaborators at the University of Geneva are implanting into the inner ear in deaf patients without vestibular function who are receiving a cochlear implant. The vestibular implant (VI) has three rate sensors and senses angular head velocity in three dimensions and provides this information to the brain by stimulation the afferent nerves innervating the three semicircular canals. Our goal is to use the VI to better understand how the brain processes this prosthetic information and uses it to generate meaningful behavioral responses including eye movements, postural control, and perception.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular Implant Stimulation
Description: VI subjects will be studied before the implant is activated (pre) and then after it is turned on (acute On); this will take about 2 hrs. Then they will have 8 hours of motion-modulated VI stimulation while they actively explore the hospital environment, after studies will be repeated (chronic On). Each set of outcome experiments will be performed twice, once with and once without low-levels of stochastic noise added to the VI stimulation provided for the 8-hour period. The noise amplitude is tailored to each patient to maximize stochastic resonance so extraction \& integration of spatial signal provided by the VI will always be the first experiment, but the order of the subsequent outcome sessions (active/passive head rotations, tilt/translation motion discrimination and VOR behavioral changes \& postural control) will be randomized. VI subjects will participate in 4 full-day sessions, each separated by at least a month.
Study: NCT01720654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPT
Description: Standardized partner notification counseling and provision of 5 partner treatment packets containing: Printed information on signs, symptoms, diagnosis, and treatment of gonorrhea and chlamydia as well as information on local testing/treatment resources; 400 mg Cefixime and 1g Azithromycin.
Study: NCT02615431

Intervention type: OTHER
Intervention: MitraClip Intervention
Study: NCT03926364

Intervention type: OTHER
Intervention: Patients with referred pain
Description: The project does not affect treatment or does not offer any intervention.
Study: NCT00200876

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Hypertonic saline
Description: To elicit pain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: To elicit pain

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Isotonic saline
Description: Non-painful control

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Description: Non-painful control
Study: NCT03670446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacists' intervention
Description: 1. Medication education: When the patient is enrolled in the intervention group, pharmacists issue an education manual to give a medical education which contains the reasons for using NOACs, the characteristics of the drug, the precautions, and how to monitor the efficacy. Pharmacists re-educate through telephone or clinic during follow-up.~2. Establish a medical record and remind their follow-up by message, phone every 2 weeks.~3. Follow-up in the 4th week and 8th week : Pharmacists recommend patients for drug therapy optimization after conducting a full pharmacotherapy review of each patient's medication regimen and remind them to test urinary occult blood every 1-3 months, detect hemoglobin and liver/kidney function every 3-6 months.
Study: NCT00723008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha Stim 100 (Cranial Electrotherapy Stimulation)
Description: cranial electrical stimulation 100 microamps
Study: NCT03155620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET, PET/CT, and/or PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET, PET/CT, and/or PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo radionuclide imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo radionuclide imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo radionuclide imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samotolisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given PO or via nasogastric or gastric tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: Receive PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray
Study: NCT04365504

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual energy X ray absorbtiometry
Description: The primary clinical application of dual-energy x-ray absorptiometry (DXA or DEXA) is the measurement of bone mineral content (BMC, g) and bone mineral density (BMD, g/cm2) of the lumbar spine and proximal femur to assess risk for osteoporosis.
Study: NCT03155620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray
Study: NCT02487810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive load
Description: Patients in the intuition arm of the study will be asked to complete a memorization task while they are answering survey questions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deliberative instructions
Description: Patients in the deliberative arm will be given instructions to take their time and deliberate on their decisions
Study: NCT01302470

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary epicardial placement of left ventricular lead
Description: Epicardial leads will be placed on the left ventricle in the area of the most dyssynchrony . the leads will be attached to a Medtronic Cardiac resynchronization/ AICD/ device
Study: NCT04886375

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spina plane block
Description: The investigators performed erector spina plane block to that patient group for postoperative analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified pectoral nerve block
Description: The investigators performed modified pectoral block to that patient group for postoperative analgesia
Study: NCT04669665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLS-002
Description: Intranasal racemic ketamine hydrochloride 90 milligrams (mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Standard of care treatment will be determined by the treating physician(s) based on clinical judgement and practice guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care treatment will be determined by the treating physician(s) based on clinical judgement and practice guidelines

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal device
Description: Device to deliver intranasal solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal device
Description: Device to deliver intranasal solution
Study: NCT04293666

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kefir
Description: 28 days supplementation kefir drink (prepared by inoculating pasteurized 9.2% reconstituted skim milk with powder kefir starter culture and fermented at 37 °C for 16 h. The fermented milk was then pasteurized at 100 °C for 30 min and freeze dried. The powder kefir starter culture used for inoculation was composed of defined lactic acid bacteria strains which contains Lactobacillus fermentum DSM 32784 (LF26), L. helveticus DSM 32787 (LH43), L. paracasei DSM 32785 (LPC12), L. rhamnosus DSM 32786 (LRH10), and Streptococcus thermophilus DSM 32788 (ST30)), 200ml/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Maltodextrin, same calorie as kefir, 200ml/day
Study: NCT00093964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide 500 mg
Description: Subjects will receive 1-hour intravenous infusion of 500 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide 2000 mg
Description: Subjects will receive 1-hour intravenous infusion of 2000 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
Study: NCT04365504

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual energy X ray absorbtiometry
Description: The primary clinical application of dual-energy x-ray absorptiometry (DXA or DEXA) is the measurement of bone mineral content (BMC, g) and bone mineral density (BMD, g/cm2) of the lumbar spine and proximal femur to assess risk for osteoporosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual energy X ray absorbtiometry
Description: The primary clinical application of dual-energy x-ray absorptiometry (DXA or DEXA) is the measurement of bone mineral content (BMC, g) and bone mineral density (BMD, g/cm2) of the lumbar spine and proximal femur to assess risk for osteoporosis.
Study: NCT01302470

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transvenous placement of left ventricular lead
Description: Conventional placement of left ventricular leads performed in the electrophysiology department.
Study: NCT02740049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VR588
Description: Evaluation of the efficacy of a novel JAK/STAT inhibitor, VR588, in isolated epithelial cells from asthma patients
Study: NCT03953963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HydraSolve T2D™
Description: The HydraSolve T2D™ System will be used to perform the combined minimally invasive laparoscopic and mini-laparotomy procedure to selectively extract excess intra-abdominal fat from the mesentery. All patients will receive standard nutritional counseling and their medications will be adjusted to achieve target levels of blood glucose control.
Study: NCT01344668

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Diabetes Education
Description: Provide enhanced diabetes education

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Diabetes Education
Description: Provide Standard Diabetes Education
Study: NCT02999828

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inactivated EV71 vaccine (KMB-17)
Description: 3.0EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
Study: NCT00853164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking exercise
Description: Subjects will be given an exercise prescription for walking 3 times a week for eight weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight training
Description: participants will be given a weight training prescription to do 3 times a week for eight weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Subjects in this arm will continue with their usual care and not start any exercise program for eight weeks.
Study: NCT03550833

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire
Study: NCT01879839

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Diet
Description: Patients receive special diet 4 days prior to contrast-agent administration.
Study: NCT04290208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: IV Acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen liquid syrup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Flavored, non-medicated (placebo) liquid syrup
Study: NCT03439163

Intervention type: DEVICE
Intervention: MRI scan
Description: All participants underwent the MRI scan
Study: NCT01871467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Study: NCT02979379

Intervention type: OTHER
Intervention: Pain

Intervention type: OTHER
Intervention: Pain
Study: NCT04290208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: IV salt solution (non-medicated)
Study: NCT03550833

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: 7 ml whole blood for Peripheral blood
Study: NCT02749357

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 30 minutes Lokomat
Description: 30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 30 minutes.~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen (20). The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 60 minutes Lokomat
Description: 30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 60 minutes.
Study: NCT04230109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Sacituzumab Govitecan via iv, predetermined dosage per protocol, two days per 21-day cycle, for 4 cycles (monotherapy cohort)